Cargando…

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

BACKGROUND: Breast cancer molecular prognostic tools that predict recurrence risk have mainly been established on endocrine-treated patients and thus are not optimal for the evaluation of benefit from endocrine therapy. The Stockholm tamoxifen (STO-3) trial which randomized postmenopausal node-negat...

Descripción completa

Detalles Bibliográficos
Autores principales:	van ‘t Veer, Laura J., Yau, Christina, Yu, Nancy Y., Benz, Christopher C., Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Esserman, Laura J., Lindström, Linda Sofie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668340/ https://www.ncbi.nlm.nih.gov/pubmed/28776283 http://dx.doi.org/10.1007/s10549-017-4428-9

Ejemplares similares

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
por: Paulsson, Janna, et al.
Publicado: (2016)

IP6K2 predicts favorable clinical outcome of primary breast cancer
por: Sandström, Josefine, et al.
Publicado: (2021)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer
por: Lindström, Linda S, et al.
Publicado: (2018)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
por: Lundgren, Christine, et al.
Publicado: (2023)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

A breast cancer gene signature for indolent disease
por: Delahaye, Leonie J. M. J., et al.
Publicado: (2017)

Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer
por: Sun, L-M, et al.
Publicado: (2014)

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
por: Lundgren, Christine, et al.
Publicado: (2020)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study
por: Colzani, Edoardo, et al.
Publicado: (2016)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden
por: Chandanos, E, et al.
Publicado: (2006)

Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer
por: Busch, Susann, et al.
Publicado: (2012)

Met and its ligand HGF are associated with clinical outcome in breast cancer
por: Veenstra, Cynthia, et al.
Publicado: (2016)

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
por: Wolf, Denise M., et al.
Publicado: (2017)

Risks of developing ulcerative colitis and Crohn’s disease in relation to silica dust exposure in Sweden: a case–control study
por: Wallden, Albin, et al.
Publicado: (2020)

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
por: Yau, Christina, et al.
Publicado: (2010)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Productivity analysis of 70 farrow-to-finish swine farms in Japan from 2013 to 2018
por: OGURA, Shun, et al.
Publicado: (2022)

Benefit of cervical screening at different ages: evidence from the UK audit of screening histories
por: Sasieni, P, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_elpeisgl6pg5qf50vm89otklff